{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=4", "query": { "condition": "Metastasis, Neoplasm", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 10742, "total_pages": 1075, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis%2C+Neoplasm&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T13:42:09.716Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00080977", "title": "High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Blumenthal Cancer Center at Carolinas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-10-21T13:42:09.716Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00080977" }, { "nct_id": "NCT03204812", "title": "Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Malignant Neoplasm in the Bone", "Prostate Adenocarcinoma", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2017-07-14", "completion_date": "2021-04-13", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-10-21T13:42:09.716Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03204812" }, { "nct_id": "NCT00810719", "title": "Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2009-04", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2018-01-10", "last_synced_at": "2026-10-21T13:42:09.716Z", "location_count": 2, "location_summary": "Los Angeles, California • Sacramento, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00810719" }, { "nct_id": "NCT01288911", "title": "A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "enzalutamide", "type": "DRUG" }, { "name": "bicalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 375, "start_date": "2011-03-22", "completion_date": "2017-11-08", "has_results": true, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-10-21T13:42:09.716Z", "location_count": 36, "location_summary": "Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 33 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Highland", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01288911" }, { "nct_id": "NCT05169437", "title": "Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Breast Tumor", "Colon Tumor, Malignant", "Lung Tumor", "Urologic Cancer", "Pancreatic Cancer", "Melanoma", "Metastatic Cancer", "Locally Advanced Solid Tumor", "Esophageal Cancer", "Endometrial Cancer", "Head and Neck Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tempus AI", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2022-03-15", "completion_date": "2024-08-27", "has_results": true, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-10-21T13:42:09.716Z", "location_count": 80, "location_summary": "Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more", "locations": [ { "city": "Yuma", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169437" }, { "nct_id": "NCT00048139", "title": "A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "capecitabine [Xeloda]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2001-10", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-21T13:42:09.716Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Fountain Valley, California • La Jolla, California + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048139" }, { "nct_id": "NCT00845039", "title": "A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer", "Rectal Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "IMC-A12 (cixutumumab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2009-05", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-10-21T13:42:09.716Z", "location_count": 3, "location_summary": "Vallejo, California • Greenville, North Carolina • Scranton, Pennsylvania", "locations": [ { "city": "Vallejo", "state": "California" }, { "city": "Greenville", "state": "North Carolina" }, { "city": "Scranton", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00845039" }, { "nct_id": "NCT02235701", "title": "Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma" ], "interventions": [ { "name": "170 mg/m2 aldoxorubicin", "type": "DRUG" }, { "name": "250 mg/m2 aldoxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "15 Years to 80 Years" }, "enrollment_count": 70, "start_date": "2014-09-02", "completion_date": "2018-05-01", "has_results": true, "last_update_posted_date": "2024-05-29", "last_synced_at": "2026-10-21T13:42:09.716Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02235701" }, { "nct_id": "NCT06557967", "title": "Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-small Cell Lung Cancer", "Lung Cancer", "Metastatic Cancer", "Brain and Central Nervous System Cancer" ], "interventions": [ { "name": "No drug", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22517, "start_date": "2024-03-01", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2024-12-09", "last_synced_at": "2026-10-21T13:42:09.716Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06557967" }, { "nct_id": "NCT03141177", "title": "A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 701, "start_date": "2017-07-23", "completion_date": "2026-04-01", "has_results": true, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-21T13:42:09.716Z", "location_count": 30, "location_summary": "Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 26 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03141177" } ] }